April 8, 2022 10:31 AM EDTUpdated 10:52 AM
R&D

BioCryst halts en­roll­ment in all stud­ies for its lead pipeline can­di­date — shares crash

Max Gelman

Senior Editor

BioCryst is tak­ing a beat­ing Fri­day morn­ing af­ter re­port­ing it would pause en­roll­ment in three stud­ies for its lead pipeline pro­gram.

In a terse …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

Up­dat­ed: Oma­da Health rose 21% in its pub­lic mar­ket de­but

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times